Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).

被引：23
|
作者：
Riudavets, Mariona
Barba, Andres
Maroto, Pablo
Sullivan, Ivana Gabriela
Anguera, Georgia
Paez, David
del Carpio, Luis
Callejo, Ana
Gonzalez Blanco, Cintia
Garcia Planellas, Esther
Castillo, Diego
Facundo, Carme
Genua, Idoia
Martin Lorente, Cristina
Virgili, Ana
Sebio, Ana
Gallego, Oscar
Lopez-Pousa, Antonio
Barnadas, Agust
Majem, Margarita
机构：
[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[2] Hosp Sant Pau, Barcelona, Spain
[3] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[4] Fundacio Puigvert, Barcelona, Spain
[5] Hosp Santa Creu & Sant Pai, Barcelona, Spain
[6] Htal Sant Pau, Barcelona, Spain
[7] Hosp Santa Creu & Sant Pau, Dept Oncol, Barcelona, Spain
[8] Univ Autonoma Barcelona, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3064
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3064
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Association of immune-related adverse (irAEs) with immunecheckpoint inhibitors (ICIs) efficacy in solid tumors
    Riudavets Melia, M.
    del Carpio, L. P.
    Gabriela Sullivan, I.
    Barba Joaquin, A.
    Maroto Rey, P.
    Anguera Palacios, G.
    Paez Lopez-Bravo, D.
    Callejo Perez, A.
    Gonzalez Blanco, C.
    Castillo Villegas, D.
    Facundo Molas, C.
    Garcia Planella, E.
    Genua Trullos, I.
    Lopez Pousa, A.
    Sebio Garcia, A.
    Martin Lorente, C.
    Virgili Manrique, A. C.
    Gallego Rubio, O.
    Barnadas Molins, A.
    Majem Tarruella, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 427 - 427
  • [2] Early incidence of immune-related adverse events (irAEs) predicts efficacy in patients (pts) with solid tumors treated with immune-checkpoint inhibitors (ICIs).
    Morehouse, Chris
    Abdullah, Shaad Essa
    Gao, Chen
    Dar, Mohammed M.
    Ranade, Koustubh
    Higgs, Brandon W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Frequency of delayed immune-related adverse events (irAEs) in hospitalized patients treated with immune checkpoint inhibitors (ICIs)
    Durbin, Sienna
    Zubiri, Leyre
    Perlman, Katherine
    Molina, Gabriel
    Jacoby, Ted
    Shah, Nishi
    Reynolds, Kerry Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Immune-related adverse events (irAEs) and survival in solid tumors treated with immune checkpoint inhibitors (ICIs): A systematic review and meta-analysis.
    Grizzi, Giulia
    Petrelli, Fausto
    Ghidini, Michele
    Ghidini, Antonio
    Ratti, Margherita
    Panni, Stefano
    Cabiddu, Mary
    Ghilardi, Mara
    Borgonovo, Karen
    Parati, Maria Chiara
    Barni, Sandro
    Tomasello, Gianluca
    Passalacqua, Rodolfo
    Berruti, Alfredo
    Brighenti, Matteo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)
    Riudavets Melia, M.
    Gabriela Sullivan, I.
    Barba Joaquin, A.
    Anguera Palacios, G.
    del Carpio, L. P.
    Molto Valiente, C.
    Camacho Arellano, S. D.
    Moron Asensio, S.
    Gomila Pons, P.
    Andres Granyo, M.
    Castillo Villegas, D.
    Facundo Molas, C.
    Garcia Planella, E.
    Gonzalez Blanco, C.
    Barnadas Molins, A.
    Gich Saladich, I.
    Majem Tarruella, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 509 - 509
  • [6] Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.
    Das, Satya
    Ciombor, Kristen Keon
    Haraldsdottir, Sigurdis
    Pumpalova, Yoanna S.
    Sahin, Ibrahim Halil
    Shyr, Yu
    Chu, Shih-Kai
    Lin, Emily Pei-Ying
    Hsu, Chih-Yuan
    Goff, Laura Williams
    Cardin, Dana Backlund
    Bilen, Mehmet Asim
    Berlin, Jordan
    Wu, Christina
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
    Daban, A.
    Gonnin, C.
    Phan, L.
    Saldmann, A.
    Granier, C.
    Lillo-Lelouet, A.
    Le Beller, C.
    Pouchot, J.
    Weiss, L.
    Tartour, E.
    Fabre, E.
    Medioni, J.
    Oudard, S.
    Vano, Y. A.
    Dragon-Durey, M. A.
    Simonaggio, A.
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [8] Immune-related adverse events (IrAEs) in patients receiving immune checkpoint inhibitors
    Ferrarini, Alessia
    Benfaremo, Devis
    Rossetti, Giulia
    Morgese, Francesca
    Pomponio, Giovanni
    Berardi, Rossana
    Gabrielli, Armando
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18
  • [9] The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors
    Fukushima, Taito
    Kobayashi, Satoshi
    Ueno, Makoto
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (09) : 949 - 958
  • [10] Immune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI)
    Rotllan, N. Baste
    Auperin, A.
    Iacob, M.
    Sampetrean, A.
    Bouguetta, D.
    Badis, L. Mayache
    Ferrand, F. R.
    Casiraghi, O.
    Blanchard, P.
    Bidault, F.
    Gorphe, P.
    Temam, S.
    Champiat, S.
    Even, C.
    Marabelle, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 470 - 470
12345